GPT and anemia: Among the efficacy population (281) and those with a median duration of treatment of 15 months, the AEs were 94.3%, the most common being anemia (42.3%), AST increase (44.5%), ALT increase (32.7%), neutropenia (31%), constipation (27%), hypertension (26.7%), and leukopenia (26.7%).